20-F: Regencell Reports Recurring Losses, Going Concern Doubt

Regencell Bioscience Holdings Limited filed its annual report for fiscal year 2025, revealing continued net losses, negative operating cash flows, and substantial doubt about its ability to continue as a going concern, despite ongoing TCM efficacy trials.

Summary

• Regencell Bioscience Holdings Limited is an early-stage bioscience company focused on research, development, and commercialization of Traditional Chinese Medicine (TCM) for neurocognitive disorders like ADHD and ASD.
• The company reported a net loss of $3.58 million for the fiscal year ended June 30, 2025, an improvement from $4.36 million in 2024 and $6.06 million in 2023.
• Net cash used in operating activities was $3.11 million in 2025, compared to $4.00 million in 2024 and $4.96 million in 2023.
• As of June 30, 2025, the company had an accumulated deficit of $25.20 million.
• The independent registered public accounting firm included a 'going concern' explanatory paragraph in the audit report, citing substantial doubt about the company's ability to continue operations.
• The company's second efficacy trial for its standardized TCM formula for ADHD and ASD patients is ongoing, with interim results showing reduced symptoms in participants.
• A 38-for-1 forward stock split was effected on June 13, 2025, resulting in 494,488,908 ordinary shares issued and outstanding as of June 30, 2025.
• The company has not generated any revenue from product sales and does not expect to until regulatory approval and commercialization of its TCM formula.
• Regencell is exploring integrating AI, blockchain, and cryptocurrency into a digital health ecosystem, currently at the concept planning stage.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including recurring losses, negative cash flow, and a 'going concern' warning. While there are positive interim results from efficacy trials and strategic plans, these are overshadowed by the fundamental financial instability, regulatory investigation, and high share price volatility. The reliance on a single TCM practitioner and unproven 'TCM brain theory' also adds to the risk.

Positives

• Interim results from the second efficacy trial for standardized TCM formula show reduced ADHD and ASD symptoms in patients, including better speech, communication, sociability, cognition, behavioral abilities, sleep quality, appetite, and bowel movement.
• The company has exclusive rights and ownership of the TCM Practitioner's formulas and intellectual property rights through strategic partnership agreements.
• Trademark certificates have been received for key brand names and the 'Sik-Kee Au TCM Brain Theory' in Hong Kong.
• Research and development costs are significantly lower ($0.95 million in 2025) compared to the average for new chemical drugs (nearly $4 billion to over $10 billion).

Negatives

• The company has a limited operating history and has incurred recurring net losses since its formation, with an accumulated deficit of $25.20 million as of June 30, 2025.
• There is substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative operating cash flows.
• No revenue has been generated from product sales, and significant revenue generation is dependent on future regulatory approvals and commercialization.
• The company has identified material weaknesses in its internal control over financial reporting, including a lack of skilled staff with U.S. GAAP and SEC reporting knowledge, absence of an internal audit function, and insufficient segregation of duties.
• The company is wholly dependent on its strategic partner, Mr. Sik-Kee Au (the TCM Practitioner), and key personnel, with the loss of whom could materially adversely affect the business.
• The market price for ordinary shares has been highly volatile, attributed in part to short squeezes or other anomalous trading activity, and may not reflect the company's value.
• The TCM brain theory, which is the basis of the company's formula, is not recognized in general literature of TCM or elsewhere, and clinical treatment results are not supported by controlled clinical data or trials.

Risks

• Inability to obtain additional financing on favorable terms or at all, which could lead to curtailment or cessation of operations.
• Failure to obtain regulatory approval or successfully commercialize standardized TCM formulas, or significant delays in doing so.
• Undesirable side effects from TCM formula candidates could delay or prevent regulatory approval, limit commercial profile, or result in negative consequences post-approval.
• Difficulties enrolling and retaining patients in research studies could delay or adversely affect TCM formula development.
• Reliance on third-party manufacturers and marketing/sales organizations, which may not perform as agreed or be available.
• Adverse publicity associated with TCM formula candidates, ingredients, or the overall TCM treatment industry could harm financial condition and operating results.
• Disruption in the supply chain of raw materials could adversely impact production and delivery.
• Potential claims by third parties regarding wrongful use or disclosure of confidential information or misappropriation of trade secrets.
• Risks associated with using new and evolving technologies like Artificial Intelligence (AI), including intellectual property risks, inaccuracy, bias, data privacy, and cybersecurity issues.
• Breaches of network or information technology and data security could have an adverse effect on the business.
• Environmental, social, and corporate governance (ESG) issues, including those related to climate change and sustainability, may negatively impact reputation and financial condition.
• Health epidemics and outbreaks could significantly disrupt ongoing research studies and delay regulatory approvals.
• Adverse global economic and political conditions, including inflation, recessions, and geopolitical instability, could affect raw material prices and patient affordability.
• Extreme price and volume fluctuations in the company's Ordinary Shares, potentially due to short squeezes, unrelated to operating performance.
• Ongoing regulatory investigation by the U.S. Department of Justice (DOJ) into trading in Ordinary Shares, which could result in substantial costs, liabilities, and diversion of management attention.
• Investment in digital assets (if pursued) is subject to significant risks and volatility, including price volatility, regulatory risk, custody/operational risk, liquidity risk, and tax/accounting impacts.
• The company's founder and CEO, Mr. Yat-Gai Au, beneficially owns 88.6% of Ordinary Shares, allowing him to exert significant control over shareholder-approved matters.
• As a foreign private issuer, the company is permitted to adopt certain home country corporate governance practices that differ from Nasdaq standards, potentially affording less protection to shareholders.
• The company may lose its foreign private issuer status, leading to significant additional costs and expenses.
• The Holding Foreign Companies Accountable Act (HFCAA) poses a risk of delisting if the PCAOB is unable to inspect the company's auditors located in Hong Kong for three consecutive years.

Future Outlook

The company aims to commercialize its standardized liquid-based TCM formula for ADHD and ASD patients, initially in Hong Kong and then globally. Future plans include engaging reputable pharmaceutical or healthcare companies for upcoming trials, integrating AI, blockchain, and cryptocurrency into a digital health ecosystem, filing patent applications, establishing centralized production facilities, and conducting further R&D on the TCM base formula for other neurological illnesses. These initiatives are currently at the concept planning stage and are subject to regulatory approvals, technical validation, and funding availability.

Management Comments

• Management believes the interim results from the second efficacy trial, showing reduced ADHD and ASD symptoms, are significant.
• Management is fully committed to continue to implement measures to remediate material weaknesses, significant deficiencies and other control deficiencies in internal control over financial reporting.

Industry Context

Regencell operates in the Traditional Chinese Medicine (TCM) industry, focusing on neurocognitive disorders like ADHD and ASD. While mainstream pharmaceutical companies offer stimulant and non-stimulant medications for symptomatic relief, Regencell aims for a natural, holistic approach to address the fundamental cause of these disorders. The TCM market in Hong Kong is regulated by the HKCMO and is highly fragmented for ADHD and ASD treatments, with no large TCM competitors. The Hong Kong government actively promotes TCM development through initiatives and funding. Regencell's approach of targeting fundamental causes with fewer side effects positions it differently from conventional symptomatic treatments, which often have various adverse effects and do not offer a cure.

Comparison to Industry Standards

• Existing ADHD medications (e.g., Ritalin, Adderall) and ASD medications (e.g., risperidone, aripiprazole) primarily offer symptomatic relief and are associated with various adverse side effects, such as restlessness, sleep difficulties, appetite loss, headaches, mood swings, and potential for abuse.
• Regencell's standardized TCM formula aims to treat the fundamental cause of ADHD and ASD, potentially offering progressive improvements over time, unlike existing drugs whose effects wear off after a few hours.
• The company's research and development costs ($0.95 million in FY2025) are substantially lower than the average R&D to marketplace cost for new chemical medicines, which can range from nearly $4 billion to over $10 billion.
• Unlike pharmaceutical manufacturers in Hong Kong who must comply with GMP certifications, TCM manufacturers are not currently required to have GMP certifications, potentially reducing initial compliance burdens for Regencell.

Management Changes

Corporate Governance

Legal Proceedings

• The company received correspondence and a subpoena from the U.S. Department of Justice (DOJ) indicating an investigation into the trading in its Ordinary Shares, requesting documents and communications concerning corporate operational, financial, and accounting matters.
• The company is cooperating with the DOJ investigation but cannot predict its ultimate resolution and expects to incur significant legal costs and other expenses.
• Potential outcomes of the investigation include fines, penalties, damages, or settlement costs in excess of insurance coverage, or administrative/injunctive proceedings against the company and/or its directors, officers, or employees.

Related Party Transactions

• Reimbursement of out-of-pocket expenses to executive management (Mr. Chung and Mr. Au) for business purposes, totaling approximately $2,539 due to Mr. Au as of June 30, 2025.
• Expenses paid to Regeneration Company Limited (a related company) for TCM formula and materials for product development: approximately $0.07 million in FY2025 and $0.09 million in FY2024.
• Reimbursement to Regeneration Company Limited for out-of-pocket R&D expenses: approximately $0.21 million in FY2025 and $0.21 million in FY2024.
• Expenses paid to Regencell Bioscience Asia Sdn. Bhd. (a related company) for research support: approximately nil in FY2025 and $0.03 million in FY2024.
• Strategic Partnership Agreement with Mr. Sik-Kee Au (CEO's father) grants the company exclusive rights and ownership of all his TCM formulas and intellectual property, in exchange for 3.0% of net revenue from commercialization to charitable institutions and reimbursement of R&D expenses.
• Supplemental Agreement with the TCM Practitioner outlines his research duties under company supervision and confidentiality obligations, with a non-compete clause for two years post-termination.

Stakeholder Impact

• Shareholders face significant risk of investment loss due to the 'going concern' doubt, recurring losses, and potential adverse outcomes from the DOJ investigation.
• Shareholders may experience continued high volatility in share price due to market speculation and potential short squeezes.
• Employees' job security could be impacted by the company's financial instability and need for additional capital.
• Customers (future patients) may benefit from the development of new TCM treatments for ADHD and ASD, but face risks related to the early stage of product development and unproven safety/efficacy in controlled trials.
• Suppliers of raw materials may face payment risks if the company's financial condition deteriorates further.
• Creditors face increased risk due to the company's recurring losses and negative cash flows, potentially impacting its ability to meet liabilities.

Next Steps

• Engage reputable pharmaceutical or healthcare companies and entrepreneurs for upcoming efficacy trials to enhance clinical development, patient recruitment, data management, and commercial foresight.
• Integrate AI, blockchain, and cryptocurrency to create a holistic digital health ecosystem for ADHD and ASD patients, including developing a patient database, securing records, and incentivizing engagement.
• File patent applications in Hong Kong and abroad to protect intellectual properties related to the TCM formula.
• Establish or partner for centralized production facilities to reduce manufacturing costs and support pCm registration.
• Brand and commercialize the standardized TCM formula, including developing new packaging and labeling, and building a marketing team in Hong Kong.
• Expand market reach to other countries, starting with the U.S., after successful commercialization in Hong Kong.
• Conduct further research and development on the TCM base formula for other neurological illnesses, disorders, and degeneration.
• Continue to implement measures to remediate identified material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

The company's financial position is highly precarious, marked by recurring net losses, negative operating cash flows, and an explicit 'going concern' warning from its auditor. This fundamental instability is a critical red flag for investors. Furthermore, the ongoing U.S. Department of Justice investigation into share trading volatility introduces significant legal and reputational risks, with unpredictable financial consequences. While the interim efficacy trial results for the TCM formula are positive, they are from uncontrolled studies and do not guarantee future regulatory approval or commercial success. The company has no current revenue from product sales and relies heavily on external financing, which may not be available on acceptable terms. The extreme share price volatility, potentially driven by short squeezes, indicates a highly speculative and risky investment. Given these severe financial, operational, legal, and market risks, a seasoned investor would likely recommend a 'strong sell' to mitigate potential further losses.

Keywords

TCM, Traditional Chinese Medicine, ADHD, ASD, Neurocognitive Disorders, Bioscience, Research and Development, SEC Filing, Form 20-F, Hong Kong, Nasdaq, Biotechnology, Healthcare, Pharmaceutical, Clinical Trials, Intellectual Property, Corporate Governance, Going Concern, Short Squeeze, AI, Blockchain, Cryptocurrency